ALDEYRA THERAPEUTICS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ALDEYRA THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2022-03-31 was $23.32K, a 99.97% decline year-over-year.
- ALDEYRA THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- ALDEYRA THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2021-09-30 was $12.12K, a 99.95% decline year-over-year.
- ALDEYRA THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2021-06-30 was $119.76M, a 693.25% increase year-over-year.
- ALDEYRA THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2021 was $189.81M, a 366.18% increase from fiscal 2020.
- ALDEYRA THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2020 was $40.72M, a 415.94% increase from fiscal 2019.
- ALDEYRA THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2019 was $7.89M, a 90.34% decline from fiscal 2018.
- ALDEYRA THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2018 was $81.67M, a 117.97% increase from fiscal 2017.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2022-03-31 | $23.32K 10-Q · filed 2023-05-04 | $119.80M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $189.81M 10-K · filed 2023-03-09 |
| 2021-09-30 | $12.12K 10-Q · filed 2022-11-10 | $189.82M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $119.76M 10-Q · filed 2022-08-05 | $212.26M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | $70.05M 10-Q · filed 2022-05-05 | $107.59M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $1.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $40.72M 10-K · filed 2022-03-17 |
| 2020-09-30 | $22.45M 10-Q · filed 2021-10-28 | $47.89M derived: sum of 4 quarters · filed 2021-10-28 |
| 2020-06-30 | $15.10M 10-Q · filed 2021-08-05 | $25.44M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $3.17M 10-Q · filed 2021-05-06 | $10.34M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $7.17M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $7.89M 10-K · filed 2021-03-11 |
| 2019-09-30 | $1.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $68.36M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $69.43M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $720.96K 10-Q · filed 2020-05-07 | $78.46M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $67.64M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $81.67M 10-K · filed 2020-03-12 |
| 2018-09-30 | $1.07M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $9.03M 10-Q · filed 2019-08-09 | |
| 2018-03-31 | $3.93M 10-Q · filed 2019-05-10 | |
| 2017-12-31 | $37.47M 10-K · filed 2019-03-08 | |
| 2016-12-31 | $12.61M 10-K · filed 2018-03-29 | |
| 2015-12-31 | $28.51M 10-K · filed 2017-03-30 | |
| 2015-03-31 | $9.04M 10-Q · filed 2015-05-14 | |
| 2014-12-31 | -$1.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | $9.98M 10-K · filed 2016-03-30 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |